Chemoembolization agents for cancer treatment

Kin Y. Tam, Ken C F LEUNG, Yi Xiang J. Wang*

*Corresponding author for this work

Research output: Contribution to journalJournal articlepeer-review

65 Citations (Scopus)


Chemoembolization has been used in the field of interventional oncology. Although practiced widely, it has only recently been demonstrated that the use of transarterial chemoembolization (TACE) provides a survival benefit based on randomized controlled trials. TACE combines the effect of targeted chemotherapy with the effect of ischemic necrosis induced by arterial embolization. Most of the TACE procedures have been based on iodized oil utilizing its microembolic and drug-carrying characteristics. Recently, there have been efforts to improve the delivery of chemotherapeutic agents to a tumor, which leads to the development of drug-eluting particles. In this review, we will describe the properties and efficacy of some chemoembolization agents which are commercially available and/or currently under clinical investigations. The potential and future of this new form of transcatheter arterial therapy for liver cancer will be discussed.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalEuropean Journal of Pharmaceutical Sciences
Issue number1-2
Publication statusPublished - 18 Sept 2011

Scopus Subject Areas

  • Pharmaceutical Science

User-Defined Keywords

  • Chemoembolization
  • Drug-eluting particles
  • Hepatocellular carcinoma
  • Lipiodol
  • Microspheres


Dive into the research topics of 'Chemoembolization agents for cancer treatment'. Together they form a unique fingerprint.

Cite this